PRECISELY Targeted Therapies for patients with cancer
With deep expertise in chemistry and structure-based drug discovery, Nuvalent is creating precisely targeted therapies for patients with cancer.
Chemistry at the Core
We design innovative small molecules that precisely inhibit clinically proven kinase targets to solve for the dual challenges of resistance and selectivity.
Built for Patients
We partner with physician-scientists to identify patient needs and the limitations of existing therapies.
Driven by Purpose
We are passionate about using our expertise to address the needs of patients with cancer.
Kari Andrews
Clinical Operations
Kari Andrews
Clinical Operations
Benjamin Lane, PhD
Technical Operations
Benjamin Lane, PhD
Technical Operations
Fareya Zubair
Regulatory Affairs
Fareya Zubair
Regulatory Affairs
Jessie Lin
Corporate Strategy &
Portfolio Management
Portfolio Management
Jessie Lin
Corporate Strategy &
Portfolio Management
Portfolio Management
Greg Smith
Regulatory
Greg Smith
Regulatory
Ruth Adams
Clinical Operations
Ruth Adams
Clinical Operations
Christopher Turner, MD
Chief Medical Officer
Christopher Turner, MD
Chief Medical Officer
Stephen McNamara
Finance
Stephen McNamara
Finance
Ray Kemper, PhD
Toxicology
Ray Kemper, PhD
Toxicology
Ashlin Miller
Program Management
Ashlin Miller
Program Management
Yuting Sun, PhD
Biology
Yuting Sun, PhD
Biology
Philip Engel
Cybersecurity & Compliance
Philip Engel
Cybersecurity & Compliance
Wenzhe Fan
Analytical Sciences
Wenzhe Fan
Analytical Sciences
Christopher Cooper, PhD
Pharmaceutical Development
Christopher Cooper, PhD
Pharmaceutical Development
Joshua Lance, JD
Legal
Joshua Lance, JD
Legal
Viola Zhu, MD, PhD
Clinical Development
Viola Zhu, MD, PhD
Clinical Development
Nathan McConarty, JD
Legal
Nathan McConarty, JD
Legal
Virginia Vetter
Regulatory Affairs
Virginia Vetter
Regulatory Affairs
Tuan Minh Nguyen, PhD
Biology
Tuan Minh Nguyen, PhD
Biology
Sibao Chen, PhD
Pharmaceutical
Development
Development
Sibao Chen, PhD
Pharmaceutical
Development
Development
Matthew Campbell
Pharmaceutical Development
Matthew Campbell
Pharmaceutical Development
Shannon Dauksis, PharmD
Program Management
Shannon Dauksis, PharmD
Program Management
Kristi Byrnes
Quality Assurance
Kristi Byrnes
Quality Assurance
Henry Pelish, PhD
Drug Discovery
Henry Pelish, PhD
Drug Discovery
Lidya Le
Clinical Operations
Lidya Le
Clinical Operations
Paula Chubet
Legal
Paula Chubet
Legal
Jeffrey Lee
Information Technologies
Jeffrey Lee
Information Technologies
Gosia Riley
Clinical Operations
Gosia Riley
Clinical Operations
Sowjanya Mangipudi
Clinical Operations
Sowjanya Mangipudi
Clinical Operations
Brenda Vienneau, CPA, CMA
Finance
Brenda Vienneau, CPA, CMA
Finance
Alex Balcom
Chief Financial Officer
Alex Balcom
Chief Financial Officer
James Porter, PhD
Chief Executive Officer
James Porter, PhD
Chief Executive Officer
Jenn Fairbanks
Clinical Operations
Jenn Fairbanks
Clinical Operations
Scot Mente, PhD
Computational Chemistry
Scot Mente, PhD
Computational Chemistry
John Soglia, PhD
Translational Development
John Soglia, PhD
Translational Development
Maureen Secord
Clinical Supply Chain
Maureen Secord
Clinical Supply Chain
Kevin Staffin
Quality Assurance
Kevin Staffin
Quality Assurance
Deb Miller, PhD, JD
Chief Legal Officer
Deb Miller, PhD, JD
Chief Legal Officer
Mikhaila Ruth
Human Resources
Mikhaila Ruth
Human Resources
Allison Magnan
GCP Quality Assurance
Allison Magnan
GCP Quality Assurance
Jesus Garza
Financial Planning &
Analysis
Analysis
Jesus Garza
Financial Planning &
Analysis
Analysis
Shashank Kulkarni, PhD
Medicinal Chemistry
Shashank Kulkarni, PhD
Medicinal Chemistry
Baudouin Gerard, PhD
Medicinal Chemistry
Baudouin Gerard, PhD
Medicinal Chemistry
Matthew Metivier
Human Resources
Matthew Metivier
Human Resources
Jason Kropp
Pharmaceutical Development
Jason Kropp
Pharmaceutical Development
Morgan Maiola
Quality Assurance
Morgan Maiola
Quality Assurance
Kristin Andrews, PhD
Computational Chemistry
Kristin Andrews, PhD
Computational Chemistry
Joshua Horan, PhD
Chemistry
Joshua Horan, PhD
Chemistry
Christian Martin
Translational Development
Christian Martin
Translational Development
Tina Kehrig
Clinical Operations
Tina Kehrig
Clinical Operations
Darlene Noci, ALM
Chief Development Officer
Darlene Noci, ALM
Chief Development Officer
Anupong
Tangpeerachaikul, PhD
Tangpeerachaikul, PhD
Biology
Anupong
Tangpeerachaikul, PhD
Tangpeerachaikul, PhD
Biology
José Lizarraga
Formulation Sciences
José Lizarraga
Formulation Sciences
News
Mar 16, 2023
Nuvalent Highlights Pipeline and Business Progress and Reports Fourth Quarter and Full Year 2022 Financial Results
Read More >
Mar 14, 2023
Nuvalent to Present New Preclinical Data on ALK-Selective Inhibitor NVL-655 at AACR Annual Meeting 2023
Read More >